Arun Swaminathan
CEO & DirectorDr. Arun Swaminathan, Ph.D. is Chief Executive Officer of Coya Therapeutics, Inc. from November 1, 2024 and serves as its Director since August 2024. Dr. Swaminathan was Chief Business Officer of Coya Therapeutics, Inc. from August 2024 to November 1, 2024. He served as Chief Business Officer of Actinium Pharmaceuticals, Inc. and had been the Chief Business & Commercial Officer since September 23, 2021. Dr. Swaminathan joined the Actinium Pharmaceuticals, Inc. on September 23, 2021. He was Chief Business Development Officer of Coya Therapeutics, Inc. since April 2023 until August 2024. He is a highly accomplished executive with experience in the global biopharmaceutical industry, which has included increasing positions of responsibility across commercial, business development and clinical roles. He served as the Chief Business Officer and Senior Vice President of Alteogen Inc. until 2022. In this role, his negotiations with Partners, including agreements with two of the top ten global pharmaceutical companies. Dr. Swaminathan joined Alteogen after they entered into an agreement with Lynkogen Inc. and gained full rights to develop the assets. As CEO and co-Founder of Lynkogen, he raised capital, in-licensed potentially transformative drug candidates to address complex metabolic diseases and advanced Lynkogen from concept to a pre-clinical stage company with a lead drug candidate ready for IND enabling studies that he successfully negotiated for out-licensing. Previously, Dr. Swaminathan held commercial and business development roles at Bristol Myers Squibb during two tenures, most recently as Worldwide Brand Director, where he managed products across the top global markets. Earlier at BMS, Dr. Swaminathan advanced from Principal scientist to associate Director, working on approved products including Nulojix, Orencia and Eliquis. Between his tenures at BMS, he spent at Covance (now Labcorp Drug Development), where he rose to Marketing Head. Dr. Swaminathan received his Ph. D., Pharmaceutical Sciences at the University of Pittsburgh and is a graduate of the Marketing Management Program at Wharton, University of Pennsylvania.
Positions
- Company NameCoya Therapeutics, Inc.Stock CodeCOYAPositionCEO & DirectorColleagues
- FGFred GrossmanPresident & Chief Medical Officer
- DSDavid S. SnyderCFO & COO
- ATAaron ThomeHead of Neuroinflammation Platform
- MFMichelle FrazierSenior Vice President of Regulatory
- AVAnabella VillalobosIndependent Director
- DADov A. GoldsteinIndependent Director
- DWDieter WeinandIndependent Director
- ALAnn L. LeeIndependent Director
